Author: Thomas Turcat
Jul2026
Ariana Pharma and USIL Therapeutics Announce AI-Powered Collaboration to Advance Development of UT-241 in Acute Radiation Syndrome
Ariana Explainable Artificial Intelligence applied to mechanistic modelling of radiation-induced oxidative stress, bridging pre-clinical evidence to clinical outcomes. Ariana Pharma® and USIL Therapeutics, a Luxembourg-based biopharmaceutical company developing innovative cytoprotective therapies, today announced a collaboration to develop a mechanistic AI model supporting the clinical evaluation of UT-241 in acute radiation syndrome (ARS). The collaboration addresses […]
Jul2026
A New Chapter: Ariana Pharma Appoints Thomas Turcat as Chief Executive Officer
Ariana Pharma announces the appointment of Thomas Turcat as Chief Executive Officer The transition marks a new chapter for Ariana Pharma as it expands the reach of its explainable AI technology with in-house drug development expertise to transform small, heterogeneous clinical cohorts into regulatory-ready results that are logical and rule-association-based while leveraging Thomas’ broad commercial […]
Nov2025
Ariana Pharmaceuticals Publishes New Study on AI-Driven Discovery of Genomic Biomarkers for Liver Toxicity Risk
Ariana Pharmaceuticals is proud to announce the publication of a new Real-World Evidence study: “eXp AI-driven Discovery of Genomic Biomarkers for Liver Toxicity Risk – A UK Biobank Case Study.” in The Pharmacogenomics Journal This research showcases how Ariana’s explainable Artificial Intelligence (eXp AI) and proprietary KEM® (Knowledge Extraction & Management) platform can identify genomic […]
Sep2024
Passing of Dr. Mohammad Afshar, Founder of Ariana Pharma
It is with profound sadness that we announce the passing of our founder, CEO and Chairman, Dr. Mohammad Afshar, on August 8th, 2024.
Dr. Afshar was a visionary leader, as well as a physician, researcher, entrepreneur, and pioneer in the field of AI and healthcare.
May2024
Ariana is 20… we’ve come a long way
Cast your mind back to when Ariana was founded… Facebook was just launching, Data Scientist had yet to be declared “the sexiest job of the 21st century,” and AI was nowhere near as widespread as today. I vividly recall a potential client asking me, “Why do you do this? This is data torture!” We talked […]
Apr2024
Ariana Pharma announces important Artificial Intelligence (AI) collaboration in precision oncology to accelerate a first-in class antibody blocking lipid metabolism for the treatment of advanced cancer
Artificial Intelligence and organoid data to accelerate the development of a first-in-class antibody in precision oncology. Paris, France and Cambridge, MA, USA, 16th April, 2024, Ariana Pharma, a leading Artificial Intelligence drug development company, announced today that it has entered a €3 million consortium sponsored by the Eurostars 3 program, led by ONA Therapeutics SL, […]
Mar2024
Ariana Pharma Announces Major Artificial Intelligence Collaboration in Cell Therapy with Leading Academic Partners Targeting Immune Regulatory T Cells
Explainable Artificial Intelligence and multi-modal clinical and omic investigations in immunotherapy applied to organ transplantation. Paris, France and Cambridge, MA, USA, March 1st, 2024. Ariana® Pharma a leading Artificial Intelligence drug development company announced today that it has entered a $10 million funded Artificial Intelligence-driven Cell Therapy collaboration with Assistance Publique – Hôpitaux de Paris (AP-HP), […]
Nov2023
ESMO 2023: Advances in the fight against cancer through artificial intelligence.
The collaboration between Ariana Pharma, Omicure, and the Léon Bérard Center has led to a breakthrough in identifying survival biomarkers across various cancer types using eXplainable Artificial Intelligence. In a study, presented at ESMO 2023 [Identification of biomarkers of survival across multiple cancer types using eXplainable Artificial Intelligence], KEM®, a proprietary Ariana Pharma technology, was […]
May2023
Ariana Pharma continues to bolster Scientific Advisory Board by adding world-leading Oncologist Pr. Jean-Yves BLAY
Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (eXp.AI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological […]
Mar2023
Ariana Pharma strengthens SAB with appointment of world-leading Neurologist Jacques Touchon
Cambridge, MA, USA and Paris, France, March 27, 2023 – Ariana Pharma, the leading Al-driven precision medicine company, has announced the appointment of Professor Jacques Touchon to its Scientific Advisory Board.